# US 2013/0259900 A1 · Adjuvant system for vaccine adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259900 A1
- Document ID: US20130259900A1
- Status: Published application
- Kind: A1
- Application number: 13/261,421
- Filed: 2011-09-27
- Published: 2013-10-03
- Earliest claimed: 2010-09-28
- Assignees: Vaxform LLC
- Inventors: Garry Morefield
- Web page: https://patentgrep.com/patent/US20130259900A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/7024: Esters of saccharides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55583: {Polysaccharides}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced Th1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions

## Claims

### Claim 1

An immunological composition comprising one or more C-type lectin(CTL) receptor ligands and one or more aluminum adjuvants and one or more antigens.

### Claim 2 (depends on 1)

The immunological composition of claim 1, wherein the CTL receptor ligand(s) are linked to the aluminum adjuvant(s).

### Claim 3 (depends on 2)

The immunological composition of claim 2, wherein the CTL receptor ligand(s) are linked by a coordinate, covalent, hydrophilic, or hydrophobic bond to the aluminum adjuvant(s).

### Claim 4 (depends on 2)

The immunological composition of claim 2, wherein the CTL receptor ligand(s) are linked through a fluoride, phosphate, sulfate, or carbonate group to the aluminum adjuvant(s).

### Claim 5 (depends on 1)

The immunological composition of claim 1, wherein the CTL receptor ligand(s) comprise monosacharides, disaccharides, polysaccharides or mixtures thereof.

### Claim 6 (depends on 5)

The immunological composition of claim 5, wherein the CTL receptor ligand(s) comprise one or more saccharides containing a terminal end phosphate group or phosphodiester backbone.

### Claim 7 (depends on 1)

The immunological composition of claim 1, wherein the aluminum adjuvant comprises aluminum oxy hydroxide, aluminum hydroxyphosphate, aluminum hydroxyphosphate sulfate, aluminum phosphate or combinations thereof.

### Claim 8 (depends on 2)

The immunological composition of claim 2 wherein the aluminum adjuvant is aluminum oxyhydroxide.

### Claim 9 (depends on 8)

The immunological composition of claim 8 wherein the CTL receptor ligand is mannose-1-phosphate.

### Claim 10 (depends on 8)

The immunological composition of claim 8 wherein the CTL receptor ligand is mannan.

### Claim 11

A method of stimulating an immune response in a mammal comprising administering to the mammal an immunological composition comprising one or more C-type lectin (CTL) receptor ligands and one or more aluminum adjuvants and one or more antigens.

### Claim 12 (depends on 11)

The method of claim 11 wherein the CTL receptor ligand(s) are linked to the aluminum adjuvant(s)

### Claim 13 (depends on 12)

The method of claim 12 wherein the CTL receptor ligand(s) are linked by a coordinate, covalent, hydrophilic, or hydrophobic bond to the aluminum adjuvant(s).

### Claim 14 (depends on 12)

The method of claim 12 wherein the CTL receptor ligand(s) are linked through a fluoride, phosphate, sulfate, or carbonate group to the aluminum adjuvant(s).

### Claim 15 (depends on 11)

The method of claim 11 wherein the CTL receptor ligand(s) comprise monosacharides, disaccharides, polysaccharides or mixtures thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein the CTL receptor ligand(s) comprise one or more saccharides containing a terminal end phosphate group or phosphodiester backbone.

### Claim 17 (depends on 11)

The method of claim 11 wherein the aluminum adjuvant comprises aluminum oxy hydroxide, aluminum hydroxyphosphate, aluminum hydroxyphosphate sulfate, aluminum phosphate or combinations thereof

### Claim 18 (depends on 12)

The method of claim 12 wherein the aluminum adjuvant is aluminum oxyhydroxide

### Claim 19 (depends on 18)

The method of claim 18 wherein the CTL receptor ligand is mannose-l-phosphate.

### Claim 20 (depends on 18)

The method of claim 18 wherein the CTL receptor ligand is mannan.

### Claim 21

An adjuvant comprising one or more C-type lectin (CTL) receptor ligands and one or more aluminum adjuvants and one or more antigens.

### Claim 22 (depends on 21)

The adjuvant of claim 21, wherein the CTL receptor ligand(s) are linked to the aluminum adjuvant(s)

### Claim 23 (depends on 22)

The adjuvant of claim 22, wherein the CTL receptor ligand(s) are linked by a coordinate, covalent, hydrophilic, or hydrophobic bond to the aluminum adjuvant(s).

### Claim 24 (depends on 22)

The adjuvant of claim 22, wherein the CTL receptor ligand(s) are linked through a fluoride, phosphate, sulfate, or carbonate group to the aluminum adjuvant(s).

### Claim 25 (depends on 21)

The adjuvant of claim 21, wherein the CTL receptor ligand(s) comprise monosacharides, disaccharides, polysaccharides or mixtures thereof.

### Claim 26 (depends on 25)

The adjuvant of claim 25, wherein the CTL receptor ligand(s) comprise one or more saccharides containing a terminal end phosphate group or phosphodiester backbone.

### Claim 27 (depends on 21)

The adjuvant of claim 21, wherein the aluminum adjuvant comprises aluminum oxy hydroxide, aluminum hydroxyphosphate, aluminum hydroxyphosphate sulfate, aluminum phosphate or combinations thereof.

### Claim 28 (depends on 22)

The adjuvant of claim 22 wherein the aluminum adjuvant is aluminum oxyhydroxide.

### Claim 29 (depends on 28)

The adjuvant of claim 28 wherein the CTL receptor ligand is mannose-1-phosphate.

### Claim 30 (depends on 28)

The adjuvant of claim 28 wherein the CTL receptor ligand is mannan.

### Claim 31

A method of making a vaccine adjuvant comprising combining a one or more C-type lectin (CTL) receptor ligands and one or more aluminum adjuvants.
